Articles from MilliporeSigma

Burlington, Massachusetts, March 18, 2026 (GLOBE NEWSWIRE) --

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, has entered into a partnership with Promega Corporation, a global life science solutions and service leader based in Madison, Wisconsin, to co-develop novel technologies that advance drug screening and discovery.

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that the Life Science business of Merck KGaA, Darmstadt, Germany has signed a definitive agreement to acquire the chromatography business of JSR Life Sciences, a leader in contract development and manufacturing, preclinical and translational clinical research, and bioprocessing solutions. The acquisition will expand the company’s downstream processing portfolio with advanced Protein A chromatography capabilities, supporting more efficient and scalable production of biopharmaceutical therapies, including monoclonal antibodies. The transaction is expected to close by the end of the second quarter of 2026.

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, has signed a non-binding Memorandum of Understanding (MoU) with Washington University (WashU) in St. Louis, Missouri, USA. The agreement marks the next chapter in a nearly century-long partnership dedicated to advancing scientific research and innovation.

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, has launched the AAW™ Automated Assay Workstation, a solution powered by Opentrons, a leader in lab automation and accessible robotics. The workstation automates routine laboratory experiments previously performed manually, reducing hands-on time and ensuring consistency in results across diverse experimental settings. This launch follows the earlier announcement of a multi-year partnership with Opentrons Labworks, Inc. to enhance laboratory workflows through automation.

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced Neoclease as the winner of the 2025 North American Advance Biotech Grant. The Boston-based biotech startup develops AI-designed gene editing therapies for Parkinson’s disease.

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today launched its global 2025 Curiosity Cube tour in Darmstadt, Germany. The solar-powered mobile science labs will bring hands-on STEM experiences to communities across North America, Europe, and for the first time, Africa. In 2025, the tour aims to reach 60,000 students worldwide. The initiative underscores the company's commitment to inspiring enthusiasm for science and technology.

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, and Opentrons Labworks, Inc., a leader in lab automation and accessible robotics, announced a multi-year agreement to automate assay kits on a custom Opentrons Flex® workstation.

The Life Science business of Merck KGaA, Darmstadt, Germany, has acquired HUB Organoids B.V. (HUB), as announced by MilliporeSigma, the U.S. and Canada business of Merck KGaA, Darmstadt, Germany in the December 17 announcement. The acquisition, which closed on December 23, 2024, is a strategic step aligned with the company’s commitment to providing novel next-generation biology solutions to the life science industry, specifically by enabling wider access to HUB’s technology for faster and more effective drug development. Terms of the deal were not disclosed.

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, announced that the Life Science business of Merck KGaA, Darmstadt, Germany has signed a definitive agreement with the intention to acquire HUB Organoids Holding B.V. (HUB). Organoids are cell culture models that functionally resemble an organ. They have the potential to speed up drug development, improve understanding of disease treatment in diverse populations, and reduce the industry’s reliance on animal testing. HUB is a pioneer in the field of organoids. The company is based in Utrecht, Netherlands and employs some 70 people. Terms of the deal were not disclosed. The transaction is expected to close at the end of December 2024.

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, today announced a $76 million expansion of its ADC manufacturing capabilities and capacity at its Bioconjugation Center of Excellence facility in St. Louis, Missouri. This investment will triple existing capacity and enhance the company’s contract development and manufacturing organization (CDMO) offering, reinforcing its commitment to clients and patients.

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, has opened its new €290 million biosafety testing facility in Rockville, Maryland, USA. Biosafety testing and analytical development are fundamental components of drug development and commercialization for traditional and novel modalities. Global demand for these services is growing at a double-digit rate1.

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, launched the first single-use reactor specifically designed to manufacture antibody drug conjugates (ADCs). ADCs are a rapidly emerging class of therapeutic agents that can target and selectively kill tumor cells, while protecting healthy ones. The Mobius® ADC Reactor is tailored precisely to meet the unique requirements for linking the necessary components. It enables biopharmaceutical companies to produce their critical therapies faster and safer.

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, today announced that the company’s Life Science business achieved EXCiPACT cGMP (current Good Manufacturing Practice) certification for Pharmaceutical Auxiliary Materials (PAMs) at its major global Cell Culture Media (CCM) production sites. EXCiPACT is a widely recognized standard for the manufacturing of non-sterile excipients. The company is the first in the industry to receive this certification.

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, today announced that the company’s Life Science business has closed the transaction to acquire Mirus Bio for approximately US$ 600 million (around € 550 million), following regulatory clearances and the fulfillment of other customary closing conditions. The acquisition is a strategic step towards the company’s ambition to offer solutions for every step of viral vector manufacturing. It also reinforces the company’s commitment to supporting customers in advancing cell and gene therapies from preclinical through commercial production. The Life Science business of Merck KGaA, Darmstadt, Germany acquired Mirus Bio from Gamma Biosciences, a life sciences platform established by global investment firm KKR.

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, and The Michael J. Fox Foundation for Parkinson's Research (MJFF), are advancing research aimed at slowing progression of Parkinson’s disease (PD). Through funding from MJFF’s “Biomarkers to Support Therapeutic Trials Program”, MilliporeSigma’s SMCxPRO® immunoassay technology has been used to help detect low levels of a biomarker associated with cell dysfunction in patients. Now, the service is available to the scientific community through support from the MJFF. This will make it possible to track the response of different therapeutic options to disease progression.

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, announced today that Siren Biotechnology has been selected as the North American winner of its 13th Advance Biotech Grant Program. The biotechnology startup, which is headquartered in San Francisco, California, USA, was selected for the development of its universal adeno-associated virus (AAV) immuno-gene therapy for cancer.

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, has launched its M-Trace® Software & Mobile App, a comprehensive data tracking solution to digitize sterility testing. The software increases overall process safety by automatically documenting data for every step of the testing process. This reduces the likelihood of deviation, false positive results, and the possibility of human error.

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, today announced the signing of a definitive agreement to acquire Mirus Bio for US$ 600 million. Mirus Bio, part of Gamma Biosciences, is a life science company based in Madison, Wisconsin, USA that specializes in the development and commercialization of transfection reagents, such as TransIT-VirusGEN®. Transfection reagents play a critical role in the production of viral vector-based gene therapies.

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, officially kicked off its global 2024 Curiosity Cube tour today in Darmstadt, Germany. The solar-powered shipping containers turned mobile science labs are once again visiting communities across North America and Europe. MilliporeSigma’s goal is to engage 45,000 students to increase access to hands-on STEM education for students through interactive science experiences.

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, launched the first all-in-one, validated genetic stability assay of its kind. The Aptegra™ CHO genetic stability assay leverages whole genome sequencing and bioinformatics to significantly accelerate biosafety testing for clients and therefore, their move into commercial production.

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, invests more than €300 million into a new Bioprocessing Production Center in Daejeon, South Korea. The new site is the largest investment by the company’s Life Science business sector in Asia-Pacific to date and demonstrates its commitment to expanding its capacities in the fast-growing region. The investment is expected to create approximately 300 additional jobs by the end of 2028.